|Articles|April 26, 2004
Recently launched trial investigates anecortave acetate for preventing AMD progression to exudative disease
Enrollment has recently begun in the anecortave acetate risk reduction(AART) study that is designed to evaluate the efficacy of that angiostaticsteroid for reducing the risk of progression from dry to exudative age-relatedmacular degeneration (AMD), said Jason S. Slakter, MD.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA grants single-patient expanded access for urcosimod in neuropathic corneal pain
2
Q&A: What’s in the glaucoma treatment pipeline?
3
Sneak peek: What’s ahead at the second International Glaucoma Symposium in Mainz, Germany
4
What attendees can learn in a day: 2nd International Glaucoma Symposium
5























